Why is Foghorn Therapeutics stock plunging today?
Foghorn Therapeutics' stock is experiencing a significant decline of 31.2% today, trading at $2.01 after announcing they would not proceed with FHD-909 (LY4050784) into dose expansion. This decision, made in conjunction with Eli Lilly, stems from a Phase 1 dose escalation review indicating that the synthetic lethality biology did not yield the necessary clinical efficacy.
The joint company also abandoned a separate SMARCA2 degrader program, effectively halting all collaboration efforts. Analyst reactions, including Wedbush cutting its rating to Neutral and slashing its price target, have contributed to today's downward momentum. The restructuring, which involves a workforce reduction of approximately 40%, has allowed the company's cash reserves to stretch into late 2029.
However, Foghorn's current pipeline is exclusively preclinical, casting doubt on its short-term prospects and prompting questions about future catalysts and potential need for new partnerships or additional funding. Unlike biotech peers in chromatin regulation and oncology, Foghorn is dealing with company-specific challenges rather than broader market strength.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
